Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
M3 ( (JP:2413) ) just unveiled an update.
M3, Inc. reported progress on its ongoing share repurchase program authorized by its board in May 2025 under Article 459 of the Companies Act, aimed at buying back up to 20 million common shares for as much as 20 billion yen. Between February 1 and February 28, 2026, the company repurchased 5,771,200 shares on the Tokyo Stock Exchange for 9,488,714,800 yen, using discretionary trading contracts.
As of February 28, 2026, total repurchases under the mandate reached 7,737,900 shares at a cumulative cost of 13,561,926,100 yen, indicating significant execution but still leaving room under the approved ceiling. The buyback underscores M3’s capital allocation strategy and may support shareholder value by reducing the free float and signaling management’s confidence, while the company retains flexibility to adjust further purchases based on market conditions.
The most recent analyst rating on (JP:2413) stock is a Buy with a Yen3000.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
More about M3
M3, Inc., listed on the TSE Prime Market under ticker 2413 and headquartered in Tokyo, operates in the digital healthcare and medical information services industry. The company focuses on online platforms and services that connect medical professionals, healthcare institutions, and related stakeholders, primarily serving the Japanese and broader global healthcare markets.
YTD Price Performance: -18.73%
Average Trading Volume: 4,914,952
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen1166.7B
For an in-depth examination of 2413 stock, go to TipRanks’ Overview page.